

PERSONAL INFORMATION

Sebastiano Giuseppe Crisafulli

Address: IRCCS Istituto Neurologico “Carlo Besta”, Via Celoria 11, 20133 Milano

Email: sebastiano.crisafulli@istituto-besta.it.

Date of birth: 26/03/1991 | **Citizenship** Italian |

PROFESSIONAL EXPERIENCE

03/2022 - present

Neurologist

IRCCS Istituto Neurologico “Carlo Besta”, Milano – Neuroimmunology and Neuromuscular Diseases Unit

03/2021 – 01/2022

Visiting Resident

IRCCS Istituto Neurologico “Carlo Besta”, Milano – Neuroimmunology and Neuromuscular Diseases Unit

12/2017 – 01/2022

Neurology residency

University of Rome La Sapienza

- Dissertation: The EPICURE study: Epigenetic signature of Multiple Sclerosis and immunological imprint of ocrelizumab via miRNA expression analysis

07/2017

Medical License (n° 45221)

Ordine dei medici chirurghi di Milano

09/2010 - 03/2017

Medical degree

Medical degree School of Medicine and Surgery

University of Milan

- Degree dissertation: Improvement of antisense oligonucleotide therapy for Spinal Muscular Atrophy: testing of new sequences and peptide mediated delivery

10/2015 – 03/2017

Clinical and research internship

IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milano – U.O. Neurologia

- Research project: Peptide-conjugated Morpholino for the treatment of Spinal Muscular Atrophy

03/2015 – 05/2015

Clinical internship

Service de Medicine interne

Centre Hospitalier Lyon Sud, Lyon, Francia

LANGUAGE SKILLS

Spoken languages	Italian, English (level C1), French (level C1)
Certifications	TOEFL iBT: score 100/120

OTHER CERTIFICATIONS

09/2020	ICH GCP R2 ONLINE TRAINING FOR SITES VERSION 2.0 GLOBAL
11/2022	Certification for standard neurological examination and assessment of Kurtzke's Functional System and Expanded Disability Status Scale in Multiple Sclerosis (Neurostatus Level C)

OTHER PERSONAL SKILLS

Participation in clinical trials	• an open-label, single-arm 4-year study to evaluate effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis – Sub investigator • a phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in adult patients with relapsing multiple sclerosis – Sub investigator • a phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab as monotherapy or in addition to baseline therapy in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) – Sub investigator • a multiple-center, non-randomized, open-label, adaptive, single-ascending dose (part 1 and part 2) and multiple-ascending dose (part 3) parallel, phase Ib study to investigate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ro7121932 following intravenous (part 1) and subcutaneous administration (parts 2 and 3) in participants with multiple sclerosis – Sub investigator • An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis – Sub investigator • A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period – Sub investigator • A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety – Sub investigator • An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis – Principal investigator • A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis – Principal Investigator • Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis – Principal Investigator
----------------------------------	--

PUBLICATIONS

Crisafulli SG, Brajkovic S, Cipolat Mis MS, Parente V, Corti S. Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis. *Mol Neurobiol.* 2018;55(4):2789-2813. doi:10.1007/s12035-017-0532-4

Ramirez A, **Crisafulli SG**, Rizzuti M, et al. Investigation of New Morpholino Oligomers to Increase Survival Motor Neuron Protein Levels in Spinal Muscular Atrophy. *Int J Mol Sci.* 2018;19(1):167. Published 2018 Jan 6. doi:10.3390/ijms19010167

Ferrazzano G, **Crisafulli SG**, Baione V, et al. Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers [published online ahead of print, 2020 Jun 5]. *J Neurol*. 2020;10.1007/s00415-020-09964-4. doi:10.1007/s00415-020-09964-4

Baione V, Belvisi D, **Crisafulli SG**, et al. Is somatosensory temporal discrimination threshold a biomarker of disease progression in multiple sclerosis? *Clin Neurophysiol*. 2020;131(12):2935-2936. doi:10.1016/j.clinph.2020.09.012

Belvisi D, Canevelli M, Baione V, et al. Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation [published online ahead of print, 2021 Feb 10]. *Mult Scler*. 2021;1352458520987541. doi:10.1177/1352458520987541

Belvisi D, Gianni C, Tartaglia M, et al. Abnormal motor surround inhibition associated with cortical and deep grey matter involvement in multiple sclerosis. *Clin Neurophysiol*. 2021;132(5):1151-1156. doi:10.1016/j.clinph.2021.01.029

Alvino B, Arianna F, Assunta B, et al. Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study [published online ahead of print, 2021 Aug 4]. *J Neurol*. 2021;10.1007/s00415-021-10737-w. doi:10.1007/s00415-021-10737-w

Zingaropoli MA, Pasculli P, Iannetta M, et al. Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. *Mult Scler J Exp Transl Clin*. 2022;8(1):20552173211065731. Published 2022 Jan 4. doi:10.1177/20552173211065731

Giossi R, Consonni A, Torri Clerici, et al. Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy. *Mult Scler Relat Disord*. 2021; In Press. doi: <https://doi.org/10.1016/j.msard.2021.103415>

Belvisi D, Tartaglia M, Borriello G, et al. Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes? *Biomedicines*. 2022;10(2):231. Published 2022 Jan 21. doi:10.3390/biomedicines10020231

Berardi A, Conte A, Cimmino L, Cimmino C, Baione V, **Crisafulli SG**, Tofani M, Tartaglia M, Fabbrini G and Galeoto G (2022) Evaluation of the Psychometric Properties of the Health Assessment Questionnaire (HAQ) in a Population of Individuals With Multiple Sclerosis. *Front. Neurol*. 13:847786. doi: 10.3389/fneur.2022.847786

ePoster: miRNA expression in immune cells: toward the identification of epigenetic signature in MS and immunological imprint of ocrelizumab. **S.G.Crisafulli**, L. Brambilla, C. Antozzi, P. Confalonieri, V. Torri Clerici, L. Scandiffio, M. Ballardini, R. Mantegazza, P. Cavalcante. ACTRIMS Forum 2022 – West Palm Beach, Febbraio 2022

ePoster: Investigating the epigenetic signature of Multiple Sclerosis and immunological imprint of ocrelizumab via miRNA analysis. S.G. Crisafulli, L. Brambilla, et al. 8th Congress of the European Academy of Neurology - Vienna, Giugno 2022

Torri Clerici V, Brambilla L, Politi PL, et al. Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study. *Mult Scler Relat Disord*. 2023;74:104711. doi:10.1016/j.msard.2023.104711

Arisi I, Malimpensa L, Manzini V, et al. Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients. *Front Immunol*. 2023;14:1234869. Published 2023 Dec 13. doi:10.3389/fimmu.2023.1234869

Giossi R, Mercenari M, Filippi M, et al. Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy. *J Neurol*. Published online June 7, 2024. doi:10.1007/s00415-024-12472-4

Mazzapicchi E, Broggi M, Restelli F, et al. Trigeminal neuralgia in multiple sclerosis: proposal of surgical flowchart and long-term outcome evaluation in a mono-institutional cohort. *Neurol Sci*. 2025;46(4):1789-1798. doi:10.1007/s10072-024-07909-7

Ciasca P, Crisafulli S, Gargiulo L, et al. Bilateral optic neuropathy as first neurological sign of Central Nervous System (CNS) involvement in indolent chronic lymphocytic leukemia. Neurol Sci. Published online March 25, 2025. doi:10.1007/s10072-025-08118-6

Scopus ID : 57194022980 - ORCID: 0009-0009-8795-1768

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".
Ai sensi degli art. 46 e 47, comma 1 del D.P.R. n.445/2000, il sottoscritto, consapevole che le dichiarazioni mendaci sono punite ai sensi del Codice penale e delle leggi speciali in materia, dichiara di essere in possesso dei titoli e delle pubblicazioni riportate nel Curriculum Vitae.

Milano, 05/11/2025

F.to
Sebastiano Giuseppe Crisafulli